Latest News and Insights

Addressing the root cause of antimicrobial resistance.

Hospital-Acquired Pneumonia: Rethinking Treatment in the Face of Antibiotic Resistance

2025-07-24T17:04:14-04:00

Hospital-acquired pneumonia (HAP) stands as one of the most significant challenges in patient care, representing a leading cause of morbidity among hospitalized patients. This formidable infection not only contributes to extended hospital stays but also leads to increased healthcare costs and a greater burden on healthcare systems. Companies like TAXIS Pharmaceuticals have the potential to transform outcomes for patients battling this condition.

Hospital-Acquired Pneumonia: Rethinking Treatment in the Face of Antibiotic Resistance2025-07-24T17:04:14-04:00

Turning the Tide: Innovations in the Fight Against Super Gonorrhea

2025-07-24T16:52:07-04:00

As we navigate the complexities of modern medicine, a quiet threat remains: multi-drug resistant gonorrhea (MDRSG, commonly referred to as Super Gonorrhea), a rapidly spreading, deadly, and highly resistant strain of Neisseria gonorrhoeae. Super gonorrhea is a prime example of how bacteria can outsmart our best defenses. At TAXIS, we are diving headfirst into the science of combating antimicrobial AMR.

Turning the Tide: Innovations in the Fight Against Super Gonorrhea2025-07-24T16:52:07-04:00

Contagion Live: A Group of Antimicrobial Compounds Shows Novelty Action Against Multidrug-Resistant Gonorrhea

2025-07-27T13:33:18-04:00

TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, discusses dihydrofolate reductase inhibitors as a novel approach to combat resistant Neisseria gonorrhoeae, a rapidly spreading, deadly, and highly resistant strain of Neisseria gonorrhoeae.

Contagion Live: A Group of Antimicrobial Compounds Shows Novelty Action Against Multidrug-Resistant Gonorrhea2025-07-27T13:33:18-04:00

$2.9 Million NIH Grant for Novel Investigational Therapeutic to Combat Antibiotic-Resistant Gonorrhea

2025-07-15T21:51:38-04:00

TAXIS has received a $2.9 million grant to further advance R&D efforts for its dihydrofolate reductase inhibitors (DHFRIs) as a novel approach to combat multi-drug resistant gonorrhea, a rapidly spreading deadly and highly resistant strain of Neisseria gonorrhoeae.

$2.9 Million NIH Grant for Novel Investigational Therapeutic to Combat Antibiotic-Resistant Gonorrhea2025-07-15T21:51:38-04:00

Innovative Approaches to Antibiotic Resistance: The Promise of TXA709

2024-12-17T13:07:27-05:00

Understanding the mechanisms behind antibiotic resistance reveals the pressing need for innovative solutions in the pharmaceutical landscape. Presenting TAXIS Pharmaceuticals' Commitment to Innovation: TXA709. TAXIS is dedicated to developing novel therapies that specifically target resistant strains of bacteria.

Innovative Approaches to Antibiotic Resistance: The Promise of TXA7092024-12-17T13:07:27-05:00

Antimicrobial Resistance (AMR) White Paper

2024-11-18T13:51:25-05:00

Our new white paper delves into the global scope of AMR, shedding light on its widespread impact and the variability of its effects across different regions. The paper outlines actionable strategies to combat AMR, such as enhancing global surveillance systems, advocating for responsible antibiotic use, investing in the development of innovative treatments, and fostering international collaboration.

Antimicrobial Resistance (AMR) White Paper2024-11-18T13:51:25-05:00

Contagion Live: Funding Isn’t Everything: Bringing Pharma to the Table for the Pasteur Act

2024-10-14T13:35:00-04:00

The prospective bill, the Pasteur Act, is one potential strategy to help in these areas, and incentivize pharmaceutical companies to develop these essential therapies. This article was originally published on contagionlive.com.  

Contagion Live: Funding Isn’t Everything: Bringing Pharma to the Table for the Pasteur Act2024-10-14T13:35:00-04:00

Genetic Engineering & Biotechnology News: The Antimicrobial Resistance Crisis

2025-07-16T12:27:51-04:00

This article was originally published in Genetic Engineering & Biotechnology News under the title of The Antimicrobial Resistance Crisis Eradicating a Global Health Threat

Genetic Engineering & Biotechnology News: The Antimicrobial Resistance Crisis2025-07-16T12:27:51-04:00
Go to Top